A Systematic Overview of Radiation Therapy Effects in Non-Small Cell Lung Cancer

References

• Williams MD, Sandler AB. The epidemiology of lung cancer'. Cancer Treat Res 2001; 105: 31–52.
   PubMedGoogle Scholar
• Lukanich JM. Tobacco and public health. Chest 1999; 116: 486S–9S.
   Google Scholar
• Taylor R, Cumming R, Woodward A, et al. Passive smoking and lung cancer: a cumulative meta-analysis. Aust N Z J Public Health 2001; 25: 203–11.
   PubMed Web of Science ®Google Scholar
• Hansen HH, Rorth M. Lung cancer. Cancer Chemother Biol Response Modif 1991; 12: 443–59.
   PubMedGoogle Scholar
• Kelly K, Mikhaeel-Kamel N. Medical treatment of lung cancer. J Thorac Imaging 1999; 14: 257–65.
   PubMedGoogle Scholar
• Sorenson S, Glimelius B, Nygren P. A systematic overview of chemotherapy effects in non-small cell lung cancer. Acta Oncol 2001; 40: 327–39.
   Google Scholar
• Hansen HH. An update on management of lung cancer. Acta Oncol 2002; 41: 500–6.
   PubMedGoogle Scholar
• Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111: 1710–7.
   PubMed Web of Science ®Google Scholar
• Vrdoljak E, Mise K, Sapunar D, et al. Survival analysis of untreated patients with non-small-cell lung cancer. Chest 1994; 106: 1797–800.
   PubMed Web of Science ®Google Scholar
• PORT Meta-analysis Trialists Group. Postoperative radio-therapy in non-small-cell lung cancer: systematic review and meta-analysis of individual patient data from nine randomised controlled trials. Lancet 1998; 352: 257-63. (M2)
   Google Scholar
• Non-small Cell Lung Cancer Collaborative Group. Che-motherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. Br Med J 1995; 311: 899-909. (M1)
   PubMedGoogle Scholar
• Clinical practice guidelines for the treatment of unresectable non-small-cell lung cancer. Adopted on May 16, 1997 by the American Society of Clinical Oncology. J Clin Oncol 1997; 15: 2996–3018.
   PubMedGoogle Scholar
• Sibley GS. Radiotherapy for patients with medically inoper-able Stage I nonsmall cell lung carcinoma: smaller volumes and higher doses-a review. Cancer 1998; 82: 433–8.
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiotherapy alone for clinical stage I nonsmall cell lung cancer. Int j Radiat Oncol Biol Phys 1997; 38: 521-5 (P2).
   Google Scholar
• Slotman BJ, Njo KH, Karim AB. Curative radiotherapy for technically operable stage I nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1994; 29: 33-7. (P2)
   Google Scholar
• Slotman BJ, Antonisse IE, Njo KH. Limited field irradiation in early stage (T1-2N0) non-small cell lung cancer. Radiother Oncol 1996; 41: 41–4. (P2)
   Google Scholar
• Sibley GS, Jamieson TA, Marks LB, et al. Radiotherapy alone for medically inoperable stage I non-small-cell lung cancer: the Duke experience. Int J Radiat Oncol Biol Phys 1998; 40: 149-54. (R2)
   Google Scholar
• Graham PH, Gebski VJ, Langlands AO. Radical radiotherapy for early nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1995; 31: 261-6. (R1)
   Google Scholar
• Krol AD, Aussems P, Noordijk EM, et al. Local irradiation alone for peripheral stage I lung cancer: could we omit the elective regional nodal irradiation? Int J Radiat Oncol Biol Phys 1996; 34: 297-302. (R1)
   Google Scholar
• Morita K, Fuwa N, Suzuki Y, et al. Radical radiotherapy for medically inoperable non-small cell lung cancer in clinical stage I: a retrospective analysis of 149 patients. Radiother Oncol 1997; 42: 31-6. (R1)
   PubMedGoogle Scholar
• Cheung PC, Mackillop WJ, Dixon P, et al. Involved-field radiotherapy alone for early-stage non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2000; 48: 703-10. (R1)
   PubMedGoogle Scholar
• Gauden S, Ramsay J, Tripcony L. The curative treatment by radiotherapy alone of stage I non-small cell carcinoma of the lung. Chest 1995; 108: 1278-82. (R1)
   Google Scholar
• Hayakawa K, Mitsuhashi N, Saito Y, et al. Limited field irradiation for medically inoperable patients with peripheral stage I non-small cell lung cancer. Lung Cancer 1999; 26: 137-42. (R2)
   Google Scholar
• Kaskowitz L, Graham MV, Emami B, et al. Radiation therapy alone for stage I non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1993; 27: 517-23. (R2)
   Google Scholar
• Kupelian PA, Komaki R, Allen P. Prognostic factors in the treatment of node-negative nonsmall cell lung carcinoma with radiotherapy alone. Int J Radiat Oncol Biol Phys 1996; 36: 607-13. (R1)
   Google Scholar
• Saunders M, Dische S, Barrett A, et al. Continuous, hyperfractionated, accelerated radiotherapy (CHART) versus conventional radiotherapy in non-small cell lung cancer: mature data from the randomised multicentre trial. CHART Steering Committee. Radiother Oncol 1999; 52: 137-48. (C1)
   PubMedGoogle Scholar
• Hayman JA, Martel MK, Ten Haken RK, et al. Dose escalation in non-small-cell lung cancer using three-dimen-sional conformal radiation therapy: update of a phase I trial. J Clin Oncol 2001; 19: 127-36. (P1)
   Google Scholar
• Mayer R, Smolle-Juettner FM, Szolar D, et al. Postoperative radiotherapy in radically resected non-small cell lung cancer. Chest 1997; 112: 954-9. (C2)
   Google Scholar
• Dautzenberg B, Arriagada R, Chammard AB, et al. A controlled study of postoperative radiotherapy for patients with completely resected nonsmall cell lung carcinoma. Groupe d'Etude et de Traitement des Cancers Bronchiques. Cancer 1999; 86: 265-73. (C1)
   Google Scholar
• Feng QF, Wang M, Wang LJ, et al. A study of postoperative radiotherapy in patients with non-small-cell lung cancer: a randomized trial. Int J Radiat Oncol Biol Phys 2000; 47: 925-9. (C1)
   PubMedGoogle Scholar
• Lafitte JJ, Ribet ME, Prevost BM, et al. Postresection irradiation for T2 NO MO non-small cell carcinoma: a prospective, randomized study. Ann Thorac Surg 1996; 62: 830-4. (C2)
   Google Scholar
• Stephens RJ, Girling DJ, Bleehen NM, et al. The role of post-operative radiotherapy in non-small-cell lung cancer: a multi-centre randomised trial in patients with pathologically staged T1-2, N1-2, MO disease. Medical Research Council Lung Cancer Working Party. Br J Cancer 1996; 74: 632–9. (Cl)
   Google Scholar
• Debevec M, Bitenc M, Vidmar S, et al. Postoperative radio-therapy for radically resected N2 non-small-cell lung cancer (NSCLC): randomised clinical study 1988-1992. Lung Can-cer 1996; 14: 99-107. (C3)
   Google Scholar
• Curran WJ, Jr, Werner-Wasik M. Issues in nonoperative management of locally advanced non-small-cell lung cancer. Oncology (Huntingt) 1998; 12: 60–6.
   PubMedGoogle Scholar
• Turrisi AT, 3rd. Innovations in multimodality therapy for lung cancer. Combined modality management of limited small-cell lung cancer. Chest 1993; 103: 56S–9S.
   Google Scholar
• Perez CA, Pajak TF, Rubin P, et al. Long-term observations of the patterns of failure in patients with unresectable non-oat cell carcinoma of the lung treated with definitive radiotherapy. Report by the Radiation Therapy Oncology Group. Cancer 1987; 59: 1874–81.
   Google Scholar
• Johnson DH, Einhorn LH, Bartolucci A, et al. Thoracic radiotherapy does not prolong survival in patients with locally advanced, unresectable non-small cell lung cancer. Ann Intern Med 1990; 113: 33–8.
   PubMed Web of Science ®Google Scholar
• Mehta MR The contemporary role of radiation therapy in the management of lung cancer. Surg Oncol Clin N Am 2000; 9: 539–61.
   PubMedGoogle Scholar
• Routh A, Hickman BT, Khansur T. Report of a prospective trial-split course versus conventional radiotherapy in the treatment of non small cell lung cancer. Radiat Med 1995; 13: 115-9. (C2)
   Google Scholar
• Cox JD, Pajak TF, Asbell S, et al. Interruptions of high-dose radiation therapy decrease long-term survival of favorable patients with unresectable non-small cell carcinoma of the lung: analysis of 1244 cases from 3 Radiation Therapy Oncology Group (RTOG) trials. Int J Radiat Oncol Biol Phys 1993; 27: 493-8. (R1)
   PubMedGoogle Scholar
• Saunders MI. Fractionation and dose in thoracic radio-therapy. Lung Cancer 1994; 10(Suppl 1): S245–52.
   Google Scholar
• Fowler J. Biological factors influencing optimum fractionation in radiation therapy. Acta Oncol 2001; 40: 712–7.
   PubMed Web of Science ®Google Scholar
• Tubiana M. Radiotherapy in non-small cell lung cancer. An overview Chest 1989; 96: 85S–7S.
   Google Scholar
• Cox JD, Azarnia N, Byhardt RW, et al. A randomized phase I/II trial of hyperfractionated radiation therapy with total doses of 60.0 Gy to 79.2 Gy: possible survival benefit with greater than or equal to 69.6 Gy in favorable patients with Radiation Therapy Oncology Group stage III non-small-cell lung carcinoma: report of Radiation Therapy Oncology Group 83–11. J Clin Oncol 1990; 8: 1543–55.
   Google Scholar
• Sause WT, Scott C, Taylor S, et al. Radiation Therapy Oncology Group (RTOG) 88-08 and Eastern Cooperative Oncology Group (ECOG) 4588: preliminary results of a phase III trial in regionally advanced, unresectable non-small-cell lung cancer. J Natl Cancer Inst 1995; 87: 198–205. (Cl)
   PubMed Web of Science ®Google Scholar
• Sause W, Kolesar P, Taylor SI, et al. Final results of phase III trial in regionally advanced unresectable non-small cell lung cancer: Radiation Therapy Oncology Group, Eastern Coop-erative Oncology Group, and Southwest Oncology Group. Chest 2000; 117: 358–64.
   PubMed Web of Science ®Google Scholar
• Saunders MI, Dische S, Grosch EJ, et al. Experience with CHART. Int J Radiat Oncol Biol Phys 1991; 21: 871–8.
   PubMed Web of Science ®Google Scholar
• Ball D, Bishop J, Smith J, et al. A randomised phase III study of accelerated or standard fraction radiotherapy with or without concurrent carboplatin in inoperable non-small cell lung cancer: final report of an Australian multi-centre trial. Radiother Oncol 1999; 52: 129-36. (C3)
   Google Scholar
• Bonner JA, McGinnis WL, Stella PJ, et al. The possible advantage of hyperfractionated thoracic radiotherapy in the treatment of locally advanced nonsmall cell lung carcinoma: results of a North Central Cancer Treatment Group Phase III Study. Cancer 1998; 82: 1037-48. (C3)
   Google Scholar
• Saunders MI, Rojas A, Lyn BE, et al. Experience with dose escalation using CHARTWEL (continuous hyperfractionated accelerated radiotherapy weekend less) in non-small-cell lung cancer. Br J Cancer 1998; 78: 1323-8. (P1)
   Google Scholar
• Mehta MP, Tannehill SP, Adak S, et al. Phase II trial of hyperfractionated accelerated radiation therapy for nonresect-able non-small-cell lung cancer: results of Eastern Coopera-tive Oncology Group 4593. J Clin Oncol 1998; 16: 3518-23. (P1)
   PubMedGoogle Scholar
• Koutaissoff S, Wellmann D, Coucke P, et al. Hyperfractio-nated accelerated radiotherapy (HART) for inoperable, non-metastatic non-small cell lung carcinoma of the lung (NSCLC): results of a phase II study for patients ineligible for combination radiochemotherapy. Int J Radiat Oncol Biol Phys 1999; 45: 1151-6. (P2)
   Google Scholar
• Inoperable non-small-cell lung cancer (NSCLC): a Medical Research Council randomised trial of palliative radiotherapy with two fractions or ten fractions. Report to the Medical Research Council by its Lung Cancer Working Party. Br J Cancer 1991; 63: 265–70.
   Google Scholar
• A Medical Research Council (MRC) randomised trial of palliative radiotherapy with two fractions or a single fraction in patients with inoperable non-small-cell lung cancer (NSCLC) and poor performance status. Medical Research Council Lung Cancer Working Party. Br J Cancer 1992; 65: 934–41. (Cl)
   Google Scholar
• Slotman BJ, Njo KH, de Jonge A, et al. Hypofractionated radiation therapy in unresectable stage III non-small cell lung cancer. Cancer 1993; 72: 1885-93. (P1)
   PubMedGoogle Scholar
• Turrisi AT, 3rd. It's about time, or is it volume, fractionation, or technique? Int J Radiat Oncol Biol Phys 1996; 36: 753–5.
   PubMed Web of Science ®Google Scholar
• Liengswangwong V, Bonner JA. Point: the potential impor-tance of elective nodal irradiation in the treatment of non-small cell lung cancer. Semin Radiat Oncol 2000; 10: 308–14.
   PubMed Web of Science ®Google Scholar
• Williams TE, Thomas CR, Jr, Turrisi AT, 3rd. Counterpoint: better radiation treatment of non-small cell lung cancer using new techniques without elective nodal irradiation. Semin Radiat Oncol 2000; 10: 315–23.
   Google Scholar
• Forssell-Aronsson E, Kjellén E, Mattsson S, et al. and the Swedish Cancer Society Investigation Group. Medical ima-ging for improved tumour characterisation, delineation and treatment verification. Acta Oncol 2002; 41: 604–14.
   Google Scholar
• Cox JD, Scott CB, Byhardt RW, et al. Addition of chemother-apy to radiation therapy alters failure patterns by cell type within non-small cell carcinoma of lung (NSCCL): analysis of radiation therapy oncology group (RTOG) trials. Int J Radiat Oncol Biol Phys 1999; 43: 505–9.
   PubMed Web of Science ®Google Scholar
• Armstrong JG. Three-dimensional conformal radiotherapy. Precision treatment of lung cancer. Chest Surg Clin N Am 1994; 4: 29–43.
   PubMedGoogle Scholar
• Graham MV, Matthews JW, Harms WB, Sr, et al. Three-dimensional radiation treatment planning study for patients with carcinoma of the lung. Int J Radiat Oncol Biol Phys 1994; 29: 1105–17.
   PubMedGoogle Scholar
• Hazuka MB, Turrisi AT, 3rd, Lutz ST, et al. Results of high-dose thoracic irradiation incorporating beam's eye view dis-play in non-small cell lung cancer: a retrospective multivariate analysis. Int J Radiat Oncol Biol Phys 1993; 27: 273–84.
   Google Scholar
• Sibley GS, Mundt AJ, Shapiro C, et al. The treatment of stage III nonsmall cell lung cancer using high dose conformal radiotherapy. Int J Radiat Oncol Biol Phys 1995; 33: 1001–7.
   PubMedGoogle Scholar
• Armstrong J, Raben A, Zelefsky M, et al. Promising survival with three-dimensional conformal radiation therapy for non-small cell lung cancer. Radiother Oncol 1997; 44: 17–22.
   PubMedGoogle Scholar
• Marom EM, McAdams HP, Erasmus JJ, et al. Staging non-small cell lung cancer with whole-body PET. Radiology 1999; 212: 803–9.
   PubMed Web of Science ®Google Scholar
• Zackrisson B, Mattsson S, Kjellén E, et al. and the Swedish Cancer Society Investigation Group. Research and develop-ment of radiation therapy in clinical routines. Acta Oncol 2003; 42: 115–22.
   Google Scholar
• Dwamena BA, Sonnad SS, Angobaldo JO, et al. Metastases from non-small cell lung cancer: mediastinal staging in the 1990s-meta-analytic comparison of PET and CT. Radiology 1999; 213: 530–6.
   PubMed Web of Science ®Google Scholar
• Bitran JD, Desser RK, DeMeester T, et al. Combined modality therapy for stage IIIMO non-oat cell bronchogenic carcinoma. Cancer Treat Rep 1978; 62: 327–32.
   PubMedGoogle Scholar
• Eagan RT, Ruud C, Lee RE, et al. Pilot study of induction therapy with cyclophosphamide, doxorubicin, and cisplatin (CAP) and chest irradiation prior to thoracotomy in initially inoperable stage III MO non-small cell lung cancer. Cancer Treat Rep 1987; 71: 895–900.
   PubMedGoogle Scholar
• Mattson K, Holsti LR, Holsti P, et al. Inoperable non-small cell lung cancer: radiation with or without chemotherapy. Eur J Cancer Clin Oncol 1988; 24: 477–82.
   PubMedGoogle Scholar
• Trovo MG, Minatel E, Veronesi A, et al. Combined radio-therapy and chemotherapy versus radiotherapy alone in locally advanced epidermoid bronchogenic carcinoma. A randomized study. Cancer 1990; 65: 400-4 (C2).
   Google Scholar
• Morton RF, Jett JR, McGinnis WL, et al. Thoracic radiation therapy alone compared with combined chemoradiotherapy for locally unresectable non-small cell lung cancer. A rando-mized, phase III trial. Ann Intern Med 1991; 115: 681–6.
   PubMed Web of Science ®Google Scholar
• Dillman RO, Seagren SL, Propert KJ, et al. A randomized trial of induction chemotherapy plus high-dose radiation versus radiation alone in stage III non-small-cell lung cancer. N Engl J Med 1990; 323: 940–5.
   PubMed Web of Science ®Google Scholar
• Le Chevalier T, Arriagada R, Tarayre M, et al. Significant effect of adjuvant chemotherapy on survival in locally advanced non-small-cell lung carcinoma. J Natl Cancer Inst 1992; 84: 58. (Cl)
   Google Scholar
• Cullen MH, Billingham LJ, Woodroffe CM, et al. Mitomycin, ifosfamide, and cisplatin in unresectable non-small-cell lung cancer: effects on survival and quality of life. J Clin Oncol 1999; 17: 3188–94. (Cl)
   PubMed Web of Science ®Google Scholar
• Brodin O, Nou E, Mercke C, et al. Comparison of induction chemotherapy before radiotherapy with radiotherapy only in patients with locally advanced squamous cell carcinoma of the lung. The Swedish Lung Cancer Study Group. Eur J Cancer 1996; 32A: 1893-900. (C2)
   Google Scholar
• Dillman RO, Herndon J, Seagren SL, et al. Improved survival in stage III non-small-cell lung cancer: seven-year follow-up of cancer and leukemia group B (CALGB) 8433 trial. J Natl Cancer Inst 1996; 88: 1210–5. (Cl)
   PubMed Web of Science ®Google Scholar
• Gregor A, Macbeth FR, Paul J, et al. Radical radiotherapy and chemotherapy in localized inoperable non-small-cell lung cancer: a randomized trial. J Natl Cancer Inst 1993; 85: 997-9. (C3)
   Google Scholar
• Wolf M, Hans K, Becker H, et al. Radiotherapy alone versus chemotherapy with ifosfamide/vindesine followed by radio-therapy in unresectable locally advanced non-small cell lung cancer. Semin Oncol 1994; 21: 42-7. (C2)
   Google Scholar
• Crino L, Latini P, Meacci M, et al. Induction chemotherapy plus high-dose radiotherapy versus radiotherapy alone in locally advanced unresectable non-small-cell lung cancer. Ann Oncol 1993; 4: 847-51. (C2)
   PubMedGoogle Scholar
• Kubota K, Furuse K, Kawahara M, et al. Role of radio-therapy in combined modality treatment of locally advanced non-small-cell lung cancer. J Clin Oncol 1994; 12: 1547-52. (C3)
   Google Scholar
• Sculier JP, Paesmans M, Lafitte JJ, et al. A randomised phase III trial comparing consolidation treatment with further chemotherapy to chest irradiation in patients with initially unresectable locoregional non-small-cell lung cancer respond-ing to induction chemotherapy. European Lung Cancer Working Party. Ann Oncol 1999; 10: 295-303. (C3)
   Google Scholar
• Gunnars B, Nygren P, Glimelius B. Assessment of quality of life during chemotherapy. Acta Oncol 2001; 40: 175–84.
   Google Scholar
• Glimelius B, Nordenskjöld B, Kjellén E, et al. and the Swedish Cancer Society Investigation Group. Interactions between chemotherapy, endocrine therapy and radiation. Acta Oncol 2002; 41: 635–8.
   Google Scholar
• Trovo MG, Minatel E, Franchin G, et al. Radiotherapy versus radiotherapy enhanced by cisplatin in stage III non-small cell lung cancer. Int J Radiat Oncol Biol Phys 1992; 24: 11-5. (C2)
   Google Scholar
• Schaake-Koning C, van den Bogaert W, Dalesio O, et al. Radiosensitization by cytotoxic drugs. The EORTC experi-ence by the Radiotherapy and Lung Cancer Cooperative Groups. Lung Cancer 1994; 10 (Suppl 1): S263-70. (Cl)
   Google Scholar
• Blanke C, Ansari R, Mantravadi R, et al. Phase III trial of thoracic irradiation with or without cisplatin for locally advanced unresectable non-small-cell lung cancer: a Hoosier Oncology Group protocol. J Clin Oncol 1995; 13: 1425–9. (Cl)
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, et al. Randomized trial of hyperfractionated radiation therapy with or without concurrent chemotherapy for stage III non-small-cell lung cancer. J Clin Oncol 1995; 13: 452–8. (Cl)
   PubMed Web of Science ®Google Scholar
• Jeremic B, Shibamoto Y, Acimovic L, et al. Hyperfractionated radiation therapy with or without concurrent low-dose daily carboplatin/etoposide for stage III non-small-cell lung cancer: a randomized study. J Clin Oncol 1996; 14: 1065–70. (Cl)
   PubMed Web of Science ®Google Scholar
• Loprevite M, Favoni RE, de Cupis A, et al. Interaction between novel anticancer agents and radiation in non-small cell lung cancer cell lines. Lung Cancer 2001; 33: 27–39.
   PubMedGoogle Scholar
• Choy H, Safran H. Preliminary analysis of a phase II study of weekly paclitaxel and concurrent radiation therapy for locally advanced non-small cell lung cancer. Semin Oncol 1995; 22: 55–7.
   PubMedGoogle Scholar
• Choy H, Devore RF, 3rd, Hande KR, et al. A phase II study of paclitaxel, carboplatin, and hyperfractionated radiation therapy for locally advanced inoperable non-small-cell lung cancer (a Vanderbilt Cancer Center Affiliate Network Study). Int J Radiat Oncol Biol Phys 2000; 47: 931–7.
   Google Scholar
• Koukourakis MI, Bahlitzanakis N, Froudarakis M, et al. Concurrent conventionally fractionated radiotherapy and weekly docetaxel in the treatment of stage Mb non-small-cell lung carcinoma. Br J Cancer 1999; 80: 1792–6.
   PubMed Web of Science ®Google Scholar
• Reckzeh B, Merte H, Pfluger KH, et al. Severe lymphocyto-penia and interstitial pneumonia in patients treated with paclitaxel and simultaneous radiotherapy for non-small-cell lung cancer. J Clin Oncol 1996; 14: 1071–6.
   PubMed Web of Science ®Google Scholar
• Clamon G, Herndon J, Cooper R, et al. Radiosensitization with carboplatin for patients with unresectable stage III non-small-cell lung cancer: a phase III trial of the Cancer and Leukemia Group B and the Eastern Cooperative Oncology Group. J Clin Oncol 1999; 17: 4–11. (Cl)
   PubMedGoogle Scholar
• Zackrisson B, Kjellén E, Glimelius B, et al. and the Swedish Cancer Society Investigation Group. Sensitising and protec-tive substances in radiotherapy and predictive assays. Acta Oncol 2002; 41: 615–22.
   Google Scholar
• Scarantino CW, McCunniff AJ, Evans G, et al. A prospective randomized comparison of radiation therapy plus lonidamine versus radiation therapy plus placebo as initial treatment of clinically localized but nonresectable nonsmall cell lung cancer. Int J Radiat Oncol Biol Phys 1994; 29: 999–1004. (Cl)
   PubMedGoogle Scholar
• Furuse K, Fukuoka M, Kawahara M, et al. Phase III study of concurrent versus sequential thoracic radiotherapy in combi-nation with mitomycin, vindesine, and cisplatin in unresect-able stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 2692–9. (Cl)
   PubMed Web of Science ®Google Scholar
• Marino P, Preatoni A, Cantoni A. Randomized trials of radiotherapy alone versus combined chemotherapy and radio-therapy in stages Ma and Mb nonsmall cell lung cancer. A meta-analysis. Cancer 1995; 76: 593–601. (Cl)
   Google Scholar
• Pritchard RS, Anthony SR Chemotherapy plus radiotherapy compared with radiotherapy alone in the treatment of locally advanced, unresectable, non-small-cell lung cancer. A meta-analysis. Ann Intern Med 1996; 125: 723-9. (M1)
   PubMedGoogle Scholar
• Payne DG. Is preoperative or postoperative radiation therapy indicated in non-small cell cancer of the lung? Lung Cancer 1994; 10(Suppl 1): S205–12.
   Google Scholar
• Rosell R, Maestre J, Font A, et al. A randomized trial of mitomycin/ifosfamide/cisplatin preoperative chemotherapy plus surgery versus surgery alone in stage IIIA non-small cell lung cancer. Semin Oncol 1994; 21: 28–33.
   PubMedGoogle Scholar
• Roth JA, Fossella F, Komaki R, et al. A randomized trial comparing perioperative chemotherapy and surgery with surgery alone in resectable stage IIIA non-small-cell lung cancer. J Natl Cancer Inst 1994; 86: 673–80.
   PubMed Web of Science ®Google Scholar
• Eberhardt W, Bildat S, Korfee S. Combined modality therapy in NSCLC. Ann Oncol 2000; 11: 85–95.
   Google Scholar
• Albain KS, Rusch VW, Crowley JJ, et al. Concurrent cisplatin/ etoposide plus chest radiotherapy followed by surgery for stages IIIA (N2) and IIIB non-small-cell lung cancer: mature results of Southwest Oncology Group phase II study 8805. J Clin Oncol 1995; 13: 1880-92. (P1)
   PubMedGoogle Scholar
• Eberhardt W, Wilke H, Stamatis G, et al. Preoperative chemotherapy followed by concurrent chemoradiation ther-apy based on hyperfractionated accelerated radiotherapy and definitive surgery in locally advanced non-small-cell lung cancer: mature results of a phase II trial. J Clin Oncol 1998; 16: 622-34. (P1)
   PubMedGoogle Scholar
• Choi NC, Carey RW, Daly W, et al. Potential impact on survival of improved tumor downstaging and resection rate by preoperative twice-daily radiation and concurrent chemother-apy in stage IIIA non-small-cell lung cancer. J Clin Oncol 1997; 15: 712-22. (P1)
   Google Scholar
• Thomas M, Rube C, Semik M, et al. Impact of preoperative bimodality induction including twice-daily radiation on tumor regression and survival in stage III non-small-cell lung cancer. J Clin Oncol 1999; 17: 1185. (P1)
   PubMedGoogle Scholar
• Macbeth FR, Bolger JJ, Hopwood P, et al. Randomized trial of palliative two-fraction versus more intensive 13-fraction radiotherapy for patients with inoperable non-small cell lung cancer and good performance status. Medical Research Council Lung Cancer Working Party. Clin Oncol 1996; 8: 167–75. (Cl)
   Google Scholar
• Rees GJ, Devrell CE, Barley VL, et al. Palliative radiotherapy for lung cancer: two versus five fractions. Clin Oncol 1997; 9: 90–5. (Cl)
   Google Scholar
• Hilaris BS, Mastoras DA. Contemporary brachytherapy approaches in non-small-cell lung cancer. J Surg Oncol 1998; 69: 258–64.
   PubMed Web of Science ®Google Scholar
• Gollins SW, Burt PA, Barber PV, et al. High dose rate intraluminal radiotherapy for carcinoma of the bronchus: outcome of treatment of 406 patients. Radiother Oncol 1994; 33: 31-40. (R1)
   Google Scholar
• Macha HN, Wahlers B, Reichle C, et al. Endobronchial radiation therapy for obstructing malignancies: ten years' experience with iridium-192 high-dose radiation brachyther-apy afterloading technique in 365 patients. Lung 1995; 173: 271-80. (R2)
   Google Scholar
• Stout R, Barber P, Burt P, et al. Clinical and quality of life outcomes in the first United Kingdom randomized trial of endobronchial brachytherapy (intraluminal radiotherapy) vs. external beam radiotherapy in the palliative treatment of inoperable non-small cell lung cancer. Radiother Oncol 2000; 56: 323–7. (Cl)
   Google Scholar
• PORT Meta-analysis Trialists Group. Postoperative radio-therapy for non-small cell lung cancer. Cochrane Database Syst Rev 2000; 2.
   Google Scholar